<DOC>
	<DOCNO>NCT02262182</DOCNO>
	<brief_summary>Pulmonary atelectasis frequent respiratory postoperative complication cardiac surgery . Classically , treatment patient base manual chest physiotherapy . Our objective evaluate interest association positive end expiratory delivery session EzPAP® device . We perform prospective monocentric , open label trial . Patients atelectasis schedule cardiac surgery cardiopulmonary bypass include . They benefit manual chest therapy randomise receive positive end expiratory pressure session twice day . The primary endpoint effect treatment atelectasis radiological score 2 day treatment . The secondary endpoint : oxygen saturation ( SpO2 ) /inspired oxygen ( FiO2 ) ratio , qualitative evaluation ventilatory function , respiratory &amp; cardiac rate , pain , inspiratory pressure ( sniff test ) , patient satisfaction , duration intensive care unit ( ICU ) hospital stay .</brief_summary>
	<brief_title>Interest Positive Expiratory Pressure ( PEP ) Delivery EzPAP® After Cardiac Surgery Management Postoperative Atelectasis</brief_title>
	<detailed_description />
	<mesh_term>Pulmonary Atelectasis</mesh_term>
	<criteria>Patients admit ICU cardiac surgery sternotomy cardiopulmonary bypass present pulmonary atelectasis extubation , diagnose chest Xray postoperative period ( day1 day 2 ) . Patients 18 year age Informed patient Cardiac arrhythmia Hemodynamic instability ( mean blood pressure &lt; 65 mmHg &gt; 95 mmHg ) Respiratory rate &gt; 35/min Undrained pneumothorax Predictable trachea intubation emergent surgery Patient oral refusal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Atelectasis , Respiratory physiotherapy , end expiratory pressure , EzPAP® , cardiac surgery</keyword>
</DOC>